Skip to content

Drug interactions

Ocrelizumab + Upadacitinib

Severity: Major

Ocrelizumab and Upadacitinib: major interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Both agents suppress immune function, and combining them raises the risk of serious infections, including opportunistic infections. Upadacitinib labeling advises against use with potent immunosuppressants.

What this interaction means in plain words

Ocrelizumab and Upadacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Ocrelizumab belongs to Central Nervous System; Upadacitinib belongs to Musculoskeletal.

Evidence level: Low

Why it happens

Additive immunosuppression via B-cell depletion and JAK inhibition.

What to do

Avoid concurrent use; if sequencing is needed, monitor closely for infection and consider immune recovery time.

What to ask your pharmacist

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Ocrelizumab and Upadacitinib, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Ocrelizumab with Upadacitinib?

MediHelp rates the interaction as major. Ocrelizumab and Upadacitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Both agents suppress immune function, and combining them raises the risk of serious infections, including opportunistic infections. Upadacitinib labeling advises against use with potent immunosuppressants.

How serious is the interaction between Ocrelizumab and Upadacitinib?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid concurrent use; if sequencing is needed, monitor closely for infection and consider immune recovery time.

What other medicines interact with Ocrelizumab?

MediHelp also lists interactions of Ocrelizumab with, for example, Adenovirus types 4 and 7 live, Influenza virus vaccine quadrivalent intranasal, Measles mumps and rubella vaccine live. The full list is on the Ocrelizumab page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in